Cancer research has entered a new era with the advent of patient-derived organoids (PDOs). These sophisticated three-dimensional (3D) models, grown from patient cells, have revolutionized our understanding of tumors and their microenvironments. By mimicking the complexity of human tumors, PDOs have
AstraZeneca has recently submitted a Biologics License Application (BLA) to the FDA for datopotamab deruxtecan (Dato-DXd), targeting accelerated approval for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that possess EGFR mutations. This submission is a significant
Comprehensive Genomic Profiling (CGP) is revolutionizing cancer treatment by enabling early detection and personalized therapy. A recent study published in the Journal of Clinical Oncology - Oncology Practice (JCO-OP) highlights the significant benefits of early CGP testing in improving clinical
The collaboration between ViaNautis Bio (ViaNautis) and Eli Lilly and Company (Lilly) marks a significant advancement in the field of genetic medicine. This partnership aims to leverage ViaNautis' cutting-edge polyNaut technology to develop precision genetic medicines that can deliver genetic
MilliporeSigma, a prominent player in the life sciences sector, has launched a transformative $76 million investment dedicated to expanding its ADC (antibody-drug conjugates) manufacturing capabilities at its St. Louis, Missouri facility. This monumental investment encapsulates the extensive
Artificial Intelligence (AI) has emerged as a transformative force in numerous sectors, and nowhere is its impact more pronounced than in the field of drug discovery. This field, traditionally marked by high costs, time-consuming processes, and a significant amount of trial and error, is witnessing
